Injectable psychoactive alkaloid composition and preparation thereof

ABSTRACT

The liquid composition includes a psychoactive alkaloid extract or synthetic psychoactive alkaloid. The alkaloids in the extract are predominantly dephosphorylated rather than phosphorylated. The injectable psychoactive alkaloid composition includes a carrier, an optional tonicity modifier, an optional antioxidant or preservative, an optional pH modifier, and optional further excipients. A process for obtaining an injectable psychoactive alkaloid composition includes dephosphorylating the alkaloid during extraction, purifying the extracted alkaloid, and standardizing it to a specific concentration by adding measured quantities of excipients.

RELATED APPLICATIONS

This application is a continuation of International Application No.PCT/CA2021/051891 filed Dec. 27, 2021, which claims the benefit of U.S.Provisional Patent Application No. 63/131,028 filed on Dec. 28, 2020,and U.S. Provisional Patent Application No. 63/139,453 filed on Jan. 20,2021, each of which are incorporated by reference in their entireties.

TECHNICAL FIELD

This application relates to an injectable composition. Morespecifically, the present invention relates to an injectable compositionof psychoactive alkaloids for human use. The present invention alsorelates to a process for preparing the injectable composition.

BACKGROUND

A psychoactive substance is a chemical substance that changes brainfunction and results in alterations in perception, mood, consciousness,cognition, or behavior. The psychoactivity of these substances mayinclude sedative, stimulant, euphoric, deliriant, and hallucinogeniceffects. These substances have been used recreationally, to purposefullyimprove performance or alter one's consciousness, and as entheogens forritual, spiritual, or shamanic purposes. Some categories of psychoactivecompounds have also shown therapeutic values and are prescribed byphysicians and other healthcare practitioners.

The active constituents of the majority of psychoactive organisms, suchas plants, fungi, animals, or yeasts, fall within a class of basic,naturally occurring, nitrogen-containing, organic compounds known asalkaloids (e.g. nicotine, morphine, cocaine, mescaline, caffeine,ephedrine, psilocin). Alkaloids have a wide range of pharmacologicalactivities including antimalarial, antiasthma, anticancer,cholinomimetic, vasodilatory, antiarrhythmic, analgesic, antibacterial,and antihyperglycemic activities. Many alkaloids have found use intraditional or modern medicine, or as starting points for drugdiscovery. Recently, psychotropic and stimulant activities ofpsychoactive alkaloids have been gaining interest from researchers astherapeutic agents for treating various conditions such as alcoholism,opioid addiction and pain to name a few.

Psychoactive alkaloids present in natural sources can be broadly dividedinto two categories, which are phosphorylated psychoactive alkaloids anddephosphorylated psychoactive alkaloids, although othernon-phosphorylatable psychoactive alkaloids may also be present in anatural source. Phosphorylated psychoactive alkaloids are phosphoricacid esters of dephosphorylated psychoactive alkaloids and arebiosynthesized in natural sources. Dephosphorylated forms of thesepsychoactive alkaloids are the bioactive forms that are converted fromthe phosphorylated form through phosphatase action or chemicalhydrolysis. In the human body, upon ingestion, phosphorylatedpsychoactive alkaloids are dephosphorylated to their correspondingdephosphorylated bioactive forms upon the action of endogenousphosphatase enzymes, which are predominantly found in the gut. Forexample, to achieve its desired effect, psilocybin must bedephosphorylated to psilocin by a phosphatase enzyme in thegastrointestinal tract.

Oral administration of phosphorylated psychoactive alkaloid compositionsvia the human gastrointestinal tract allows the conversion of thephosphorylated form to the corresponding biological effectivedephosphorylated form. Additionally, the oral route of administration isconvenient and ensures patient compliance. However, bioavailability ofactive pharmaceutical ingredients (APIs) via enteric administration isheavily dependent on an ingredient's ability to be absorbed across theintestinal epithelium and first pass metabolism. Enteric routes ofadministration also pose challenges such as long onset of action,gastric irritation, etc. Further, the ingestion of dosage forms via theoral route, which involves chewing or swallowing, is problematic forchildren and geriatric patients.

Additionally, psychoactive alkaloid extracts are often present in theform of a sticky tar, which is difficult to handle or standardize intocompositions with specific amounts of psychoactive alkaloids that can beformulated into desired dosage forms.

Because of this there are attempts by researchers and companies tocreate non-ingestive delivery methods for these alkaloids e.g.psilocybin. These include nasal sprays, inhalers, sublingual absorptionetc. However, since psilocybin is the phosphorylated prodrug of thepsilocin, a dephosphorylation process must occur in order for thedesired effect to occur. The endogenous phosphatase enzyme isresponsible for this dephosphorylation and is predominantly found in thegut. These non-ingestive delivery methods are suboptimal because theydeliver a phosphorylated alkaloid to an area of the body where little tono dephosphorylation will occur.

This background information is provided to reveal information believedby the applicant to be of possible relevance to the present invention.No admission is necessarily intended, nor should be construed, that anyof the preceding information constitutes prior art against the presentinvention.

SUMMARY OF INVENTION

The inventors have realized that there is a need for a non-ingestivepsychoactive alkaloid composition capable of providing desired levels ofbioactivity in the systemic circulation. In particular, there is needfor a non-ingestive psychoactive alkaloid composition that allows forrapid delivery of the psychoactive alkaloid into the systemiccirculation, and does not adversely affect the bioavailability of thepsychoactive alkaloid, thus allowing the psychoactive alkaloid toachieve the desired psychoactive effects. The psychoactive alkaloidcomposition is an injectable composition made with a predominantlydephosphorylated psychoactive alkaloid, a solvent carrier, an optionalpreservative or antioxidant, an optional tonicity modifier, andoptionally one or more further excipients. Use of a dephosphorylatedpsychoactive alkaloid allows for a non-ingestive delivery mechanism,with its attendant benefits and without the downside of a lack of anavailable dephosphorylation process within the body. The psychoactivealkaloids may be extracted or synthetic, and may initially be providedin either powder or liquid form.

By preparing non-oral delivery systems which avoid the use ofphosphorylated alkaloids (i.e. delivering psilocin rather thanpsilocybin), a non-ingestive delivery mechanism is provided with itsattendant benefits without the major downside of the lack ofdephosphorylation required to achieve desired psychoactive effects.

Disclosed is a liquid, injectable psychoactive alkaloid compositioncomprising, by weight: 0.1-50% of a psychoactive alkaloid component;25-89.9% of a solvent carrier; 0-20% of a tonicity modifier; 0-10% of apH modifier; 0-5% of a bioavailability enhancer; and 0-5% of anantioxidant, preservative or mixture thereof.

Also disclosed is a process for obtaining a liquid, injectablepsychoactive alkaloid composition, the process comprising: extractingpsychoactive alkaloid from a dried powdered psychoactive alkaloid sourceusing an acidified solvent with a pH of 3.5 or lower, to obtain apsychoactive alkaloid liquid; adjusting the pH of the psychoactivealkaloid liquid to a pH ranging from 4.5-5.5; evaporating the acidifiedsolvent from the psychoactive alkaloid liquid to obtain a psychoactivealkaloid extract; and mixing, by weight, 0.1-50% of the psychoactivealkaloid extract, 25-89.9% of a solvent carrier, 0-20% of a tonicitymodifier; and 0-5% of an antioxidant to form the liquid, injectablepsychoactive alkaloid composition.

This summary does not necessarily describe all features of the inventionin detail and is not intended to limit the invention.

BRIEF DESCRIPTION OF DRAWINGS

The following drawings illustrate embodiments of the invention, whichshould not be construed as restricting the scope of the invention in anyway.

FIG. 1 illustrates the steps of a process for obtaining a psychoactivealkaloid extract with dephosphorylation control, according to anembodiment of the present invention.

FIG. 2 illustrates the steps of a process for obtaining a purifiedpsychoactive alkaloid extract according to an embodiment of the presentinvention.

FIG. 3 illustrates a process for obtaining an injectable psychoactivealkaloid composition, according to an embodiment of the presentinvention.

FIG. 4 illustrates a schematic diagram of the apparatus used forobtaining injectable psychoactive alkaloid compositions according toembodiments of the present invention.

DESCRIPTION A. Glossary

To facilitate the understanding of this invention, a number of terms aredefined below. Terms defined herein have meanings as commonly understoodby a person of ordinary skill in the areas relevant to the presentinvention. Terms such as “a”, “an” and “the” are not intended to referto only a singular entity but include the general class of which aspecific example may be used for illustration. Terms such as “organism”,“alcohol” and “alkaloid” are used as uncountable nouns, unless thecontext clearly indicates that a specific type of organism, alcohol oralkaloid is being referred to. The terminology herein is used todescribe specific embodiments of the invention, but its usage does notdelimit the invention, except as outlined in the claims.

The term “psychoactive alkaloid” used herein refers to alkaloids thatupon ingestion or other bodily intake are capable of changing brainfunction, for example resulting in alterations in perception, mood,consciousness, cognition, or behavior. The psychoactive alkaloid towhich the present invention applies is predominantly a dephosphorylatedpsychoactive alkaloid, rather than a phosphorylated alkaloid ornon-phosphorylatable alkaloid.

The term “psychoactive alkaloid source” used herein refers to anorganism such as a fungus, a mycelium, a spore, a plant, a bacterium, ananimal or a yeast, which has in it a phosphorylated psychoactivealkaloid, a dephosphorylated psychoactive alkaloid, or a combination orboth. The source of the psychoactive alkaloid can also be an extract ora solution with a phosphorylated psychoactive alkaloid, adephosphorylated psychoactive alkaloid, or a combination of both.

The term “phosphorylatable” refers to psychoactive alkaloids that havephosphorylated derivatives and includes psychoactive alkaloids in boththeir phosphorylated and dephosphorylated forms.

The term “psychoactive alkaloid composition” used herein can also bereferred to as “composition” and describes a mixture of a psychoactivealkaloid possibly with extracted impurities, and one or more excipients.The composition can be of pharmaceutical, nutraceutical, or veterinariangrade.

The term “psychoactive alkaloid liquid” used herein refers topsychoactive alkaloid obtained in liquid form after a dried powderedbiomass of a psychoactive alkaloid source has been extracted using anacidified solvent or a basified solvent. The liquid form can be asolution or a slurry, and may or may not be filtered.

The term “purified psychoactive alkaloid solution” refers to a solutionof one or more desired psychoactive alkaloids, where the solution isfree of impurities or contains fewer impurities compared to a similarpsychoactive alkaloid solution that has not undergone any purification.The purified solution is obtained after a psychoactive alkaloidextracted from its source has been purified using a resinous material asdescribed herein. Complete or partial evaporation of solvent from thepurified psychoactive alkaloid solution results in a purifiedpsychoactive alkaloid extract.

The term “psychoactive alkaloid extract” used herein refers to apsychoactive alkaloid extract obtained by an extraction processdescribed herein or other extraction process. The extract can be in apowdered, semi-solid or slurry form.

The term “purified psychoactive alkaloid extract” used herein refers toa psychoactive alkaloid extract that has been purified using resinousmaterial as described herein or otherwise. The purified psychoactivealkaloid extract has fewer impurities compared to a similar psychoactivealkaloid extract that has not undergone any purification. The extractcan be in a powdered or a semi-solid or slurry form.

As used herein, the expression “standardization of” or “standardizing”the psychoactive alkaloid extract refers to adding a measured amount ofone or more excipients to a psychoactive alkaloid extract or syntheticpsychoactive alkaloid to achieve a psychoactive alkaloid composition oran injectable psychoactive alkaloid composition. Addition of apre-calculated percentage concentration of non-active pharmaceuticalingredients to the psychoactive alkaloid extract or syntheticpsychoactive alkaloid results in standardization of the psychoactivealkaloid composition or injectable psychoactive alkaloid composition.The standardization process ensures that the psychoactive alkaloidcomposition or injectable psychoactive alkaloid composition has aspecific amount of total psychoactive alkaloid content in thecomposition. This specific amount may be accurate up to two or threesignificant figures. This specific amount is defined as a percentage byweight and can be selected by a person of skill in the art according topreference.

The term “resin” as used herein is intended to refer to a solid orhighly viscous substance of plant, mineral, or synthetic origin that hasbeen typically converted into a polymer. Resins are usually mixtures oforganic compounds. They are typically used in chromatographic techniquesas a stationary phase to purify and separate compounds depending ontheir polarity. Resins can be physically or chemically modified toprovide specificity to bind or repel particular molecules withinsometimes very complex mixtures.

As used herein, the term “ion exchange resin” refers to an insolubleorganic polymer containing charged groups that attract and holdoppositely charged ions present in a surrounding solution in exchangefor counterions previously held. Suitable ion exchange resins to be usedherein contain cationic groups that attract and hold anions present in asurrounding solution and are sometimes referred to as “anionion-exchange resins”. Similarly, other ion exchange resins used hereincontain anionic groups that attract and hold cations present in asurrounding solution and are sometimes referred to as “cationion-exchange resins”.

The term “macroporous resin” as used herein refers to a nonionic, cationor anion resin with very small, highly cross-linked polymer particleswith tiny channels. Macroporous resins are generally used for theadsorption of organic constituents due to their hydrophobic propertiesand are thus used to separate and purify compounds. The adsorptioncapacity of macroporous resins not only correlates with the physical andchemical properties of the adsorbent, but also with the size andchemical features of the adsorbed substance.

The term “adsorbed psychoactive alkaloid” refers to one or morealkaloids that are adsorbed onto a resinous material.

The term “purified water” includes deionized water, distilled water,reverse osmosis water, or otherwise purified water which issubstantially without free ions.

As used herein, the term “specific amount” when referring to a totalpsychoactive alkaloid content means a desired percentage, accurate, forexample, to one or two decimal places or one, two or three significantfigures, of total psychoactive alkaloid content in a psychoactivealkaloid composition or a psychoactive alkaloid extract. The specificamount is defined as a percentage by weight and can be selected by aperson of skill in the art according to preference.

The term “specific pH” herein refers to a definite pH value of a solventor a psychoactive alkaloid liquid obtained by adding an acidifiedsolvent or a basified solvent.

The term “desired amount” herein refers to an amount of a phosphorylatedpsychoactive alkaloid or a dephosphorylated psychoactive alkaloid in atotal psychoactive alkaloid content, in the psychoactive alkaloidliquid, extract or composition. The amount of each of these alkaloids iscontrolled by the process for making the psychoactive alkaloid extractor psychoactive alkaloid composition. The amounts can be altered by aperson of skill in the art according to preference. The amounts areusually percentages by weight that may be accurate up to two or threesignificant figures, or they may be ranges.

The “impurities” herein are commonly undesired, but not necessarilyharmful, substances encountered while extracting psychoactive alkaloidsfrom a natural source. Impurities may include sugars, carbohydrates,chitin, chitosan, fats, minerals, waxes, and/or proteins. The impuritiesbeing removed from a psychoactive alkaloid extract will vary dependingon the source of the psychoactive alkaloid. Their removal increases theconcentration of the desired psychoactive alkaloids remaining in theextract.

The term “total psychoactive alkaloid content” used herein refers to thetotal amount of psychoactive alkaloid present in the psychoactivealkaloid composition. The amount is usually a percentage by weight thatmay be accurate up to two or three significant figures.

The term “active pharmaceutical ingredient” or “API” used herein refersto an active ingredient in a pharmaceutical composition orpharmaceutical drug that is biologically active.

The term “non-active pharmaceutical ingredients” used herein refers tonon-medical ingredients of a composition which do not have any have anyeffect on the body. They are generally used to improve stability of acomposition's formulation, bulk up formulations, and more. The term asused herein includes a polymer, a carrier, and one or more otherexcipients.

The term “bioavailability” used herein refers to the fraction of an APIthat is available in the systemic circulation after administration. Thisfraction of API in the systemic circulation is therefore available fordelivery to the intended site of action.

The term “rapid delivery” means initial immediate rapid release anddelivery of an API from a composition. The rapid delivery is typicallyfollowed by a time-dependent reduction in release of the API from thecomposition or device and delivery of the drug to the plasma.

The term “excipient” means any component added to an active ingredientto make a composition. An excipient is inert in relation to the activeingredient, in that it essentially does not act in the same way as theactive ingredient. An excipient may be completely inert, or it may havesome other property that protects the integrity of the active ingredientor assists its uptake into the human body. There are multiple types ofexcipient, each having a different purpose, and a given excipient mayfulfill more than one purpose. Examples of types of excipient includepermeation enhancers, mucoadhesive polymers, surfactants, thickeningagents, gelling polymers, flowability agents, flavoring agents,sweeteners, colorants, palatants, antioxidants, bioavailabilityenhancers, viscosity modifying agents, tonicity agents, drug carriers,sustained-release agents, comfort-enhancing agents, emulsifiers,solubilizing aids, lubricants, carriers, binders, disintegrants andstabilizing agents. Specific excipients include pectin, rice husks,rice, xanthum gum, gum arabic, beta cyclodextrin, alpha cyclodextrin,microcrystalline cellulose, sorbitol, dextrose, guar gum, acacia gum,cellulose gum, talc, magnesium stearate.

The term “preservative” means an excipient that is added to thecomposition to prevent microbial growth or microbial degradation of thecomposition.

The term “desired psychoactive effects” herein refers to intendedchanges in nervous system function resulting in alterations inperception, mood, consciousness, cognition, or behavior that areachieved upon administration of a psychoactive alkaloid composition.

The term “therapeutic” is intended to qualify the amount of activeingredients required in the treatment of a disease or disorder or on theeffecting of a clinical endpoint.

Reference to “treatment” of a patient is intended to includeprophylaxis. Treatment may also be preemptive in nature, i.e., it mayinclude prevention of disease. Prevention of a disease may involvecomplete protection from disease, for example as in the case ofprevention of infection with a pathogen or may involve prevention ofdisease progression. For example, prevention of a disease may not meancomplete foreclosure of any effect related to the diseases at any level,but instead may mean prevention of the symptoms of a disease to aclinically significant or detectable level. Prevention of diseases mayalso mean prevention of progression of a disease to a later stage of thedisease.

B. Composition

The embodiments of the injectable psychoactive alkaloid composition orinjectable composition described herein are in the liquid form, made bycombining a psychoactive alkaloid extract, a solvent carrier or carrier,optionally an antioxidant or preservative, an optional tonicitymodifier, and optionally one or more further excipients. Optionally, apH modifier is added to the composition. In some embodiments, theinjectable psychoactive alkaloid composition is administrated via asubcutaneous, an intravenous or an intramuscular injection.

In some embodiments, the psychoactive alkaloid extract has a desiredamount of a phosphorylated psychoactive alkaloid and a desired amount ofa dephosphorylated psychoactive alkaloid. That is, the proportion ofdephosphorylated to phosphorylated alkaloids is controlled. In someembodiments, a majority or all of the alkaloids are dephosphorylated. Insome embodiments, the psychoactive alkaloid extract additionallyincludes other psychoactive alkaloids that are not phosphorylatable. Insome embodiments, a synthetic psychoactive alkaloid is used instead ofthe psychoactive alkaloid extract. In some embodiments, the syntheticpsychoactive alkaloid has no phosphorylated alkaloid content, i.e. thealkaloid content is entirely dephosphorylated psychoactive alkaloid.

The injectable compositions allow the delivery of psychoactive alkaloidsinto the patient's bloodstream while bypassing the gastrointestinaltract and the hepatic metabolism. As such, they result in a higherbioavailability of the dephosphorylated psychoactive alkaloids to thepatient compared to ingested forms, which may suffer degradation enroute to the bloodstream. This also allows for lower dosage requirementsof psychoactive alkaloids to achieve the desired psychoactive effects.

The amounts of the components mixed together by weight to form theinjectable composition are summarized in TABLE 1.

TABLE 1 Component Range/% Psychoactive synthetic or extract 0.1-50 Carrier  25-89.9 Preservative or antioxidant 0-5  Tonicity modifier 0-20

In another embodiment, the amounts of the components of the injectablecomposition mixed together by weight are shown in the TABLE 2.

TABLE 2 Component Range/% Psychoactive synthetic or extract 10-20Carrier 60-80 Preservative or antioxidant 2.5-5  Tonicity modifierEnough to bring tonicity to that of human plasma pH modifier Enough tobring pH 5 +/− 0.25, e.g. up to 10%B1. Psychoactive Component

The psychoactive component is either an extract or synthetic, and may beliquid or solid.

When it is an extract, it may be obtained from any psychoactiveorganism, such as a plant, fungus or animal, and the extract may be insolid or liquid form, the liquid form being, for example, a slurry or asolution. In some embodiments, the psychoactive component is apsychoactive alkaloid extract that forms 0.1% to 50% by weight of thecomposition. In other embodiments, the psychoactive alkaloid extractforms 10% to 20% by weight of the composition.

In some embodiments, the psychoactive alkaloid extract has a totalpsychoactive alkaloid content ranging from 0.1% to 99% by weight of theextract. In other embodiments, the psychoactive alkaloid extract has atotal psychoactive alkaloid content ranging from 1% to 75% by weight ofthe extract. In yet other embodiments, the psychoactive alkaloid extracthas a total psychoactive alkaloid content ranging from 10% to 30% byweight of the extract. In other embodiments, the psychoactive alkaloidcomposition has a total psychoactive alkaloid content ranging from15.00% to 25.00% by weight of the composition. The total psychoactivealkaloid content in the psychoactive alkaloid extract may be defined asa percentage up to two decimal places.

In some embodiments, the psychoactive alkaloid extract further includesnaturally occurring substances. The naturally occurring substances arepresent in the psychoactive alkaloid extract in a concentration rangingfrom 1% to 99.9% by weight. The naturally occurring substances referredto herein include fats, sugars, carbohydrates, chitin, chitosan,minerals, waxes, proteins, or any combination selected therefrom. Thesenaturally occurring substances may have side effects when injected aspart of the composition. The concentration range of the naturallyoccurring substances in the psychoactive alkaloid extract or thepurified psychoactive alkaloid extract will vary due to various factorsfor example, but not limited to, the source of the psychoactive alkaloidextract, the extraction technique used, the efficiency of the extractionprocess, and the amount of the psychoactive alkaloid in the extract.

The psychoactive component includes predominantly dephosphorylatedpsychoactive alkaloid in comparison to phosphorylated psychoactivealkaloid. In some embodiments, the desired amount of thedephosphorylated psychoactive alkaloid is over 50% by weight of thetotal psychoactive alkaloid content in the psychoactive alkaloidextract, and the desired amount of the phosphorylated psychoactivealkaloid is the remainder. In some embodiments, the desired amount ofthe dephosphorylated psychoactive alkaloid is 100% by weight of thetotal psychoactive alkaloid content in the psychoactive alkaloidextract. In some embodiments, the desired amount of the dephosphorylatedpsychoactive alkaloid is 100% by weight of the total phosphorylatablepsychoactive alkaloid content in the psychoactive alkaloid extract.

In some embodiments, the psychoactive alkaloid extract is present in itspurified form i.e. as a purified psychoactive alkaloid extract. In someembodiments, the purified psychoactive alkaloid extract has a totalpsychoactive alkaloid content ranging from 10% to 99% by weight of thepurified psychoactive alkaloid extract. The naturally occurringsubstances are present in the purified psychoactive alkaloid extract ina concentration ranging from 1% to 90% by dry weight. In someembodiments, the purified psychoactive alkaloid extract has a totalpsychoactive alkaloid content ranging from 10.00% to 30.00% by weight ofthe purified psychoactive alkaloid extract.

In some embodiments, the desired amount of the dephosphorylatedpsychoactive alkaloid is over 50% by weight of the total psychoactivealkaloid content in the purified psychoactive alkaloid extract, and thedesired amount of the phosphorylated psychoactive alkaloid is theremainder. In some embodiments, the desired amount of thedephosphorylated psychoactive alkaloid is 100% by weight of the totalpsychoactive alkaloid content in the purified psychoactive alkaloidextract. In some embodiments, the desired amount of the dephosphorylatedpsychoactive alkaloid is 100% by weight of the total phosphorylatablepsychoactive alkaloid content in the purified psychoactive alkaloidextract.

The composition of the present invention has a total psychoactivealkaloid content present in a specific amount. In some embodiments, thespecific amount of the total psychoactive alkaloid content is accurateto one significant figure. In other embodiments, the specific amount ofthe total psychoactive alkaloid content is accurate to two, three orfour significant figures. The presence of the total psychoactivealkaloid content in a specific amount in the composition is possibledespite the variation of psychoactive content in different batches ofthe extract, because the content in each batch is known and the amountof each extract used can be chosen accordingly.

In some embodiments, the phosphorylated alkaloid is psilocybin,baeocystin, norbaeocystin, aeruginascin, an alkaloid with similarproperties, or any combination selected therefrom; and thedephosphorylated alkaloid is psilocin, bufotenine, bufotenidine,norpsilocin, 4-hydroxytryptamine (4-HT),N,N,N-trimethyl-4-hydroxytryptamine, 4-hydroxy-N,N,N-trimethyltryptamine(4-HO-TMT), an alkaloid with similar properties, or any combinationselected therefrom.

In some embodiments, the psychoactive component is a syntheticpsychoactive alkaloid component. In some embodiments, the syntheticpsychoactive alkaloid component has a psychoactive alkaloid content ofup to 99%, and the amount of the synthetic psychoactive alkaloidcomponent is 0.1-50% by weight of the composition. In some embodiments,the amount of synthetic psychoactive alkaloid component is 6-10% byweight of the composition. The psychoactive alkaloid in the syntheticpsychoactive alkaloid component may be entirely dephosphorylatedpsychoactive alkaloid, for example psilocin. In other embodiments, thepsychoactive alkaloid in the synthetic psychoactive alkaloid componentmay be partly dephosphorylated psychoactive alkaloid, for examplepsilocin and partly phosphorylated, for example psilocybin.

Where the psychoactive component is in a liquid form, whether an extractor synthetic, the dephosphorylated alkaloid is at its isoelectric pointor, in other words, is in its freebase form. Where the dephosphorylatedalkaloid is psilocin, the liquid psychoactive component has a pH of8.47±0.25, i.e. the isoelectric point of psilocin. Where thepsychoactive component is in a powder form, it will have pH of 8.47±0.25if mixed with pure water. In some embodiments, the pH of thepsychoactive component has a pH in the range of 4-10.

B2. Carrier

The carrier or solvent carrier is individually chosen from or is amixture of any of water, ethanol, polyethylene glycol (PEG), PEG 300,PEG 400, PEG 600, PEG 3350, PEG 4000, propylene glycol (PG), glycerine,benzyl benzoate, castor oil, cottonseed oil, N—N dimethylacetamide,N-methyl 2-pyrrolidone, peanut oil, poppyseed oil, safflower oil, sesameoil, soybean oil and vegetable oil. In some embodiments, the amount ofcarrier introduced into the composition is 25-89.9% by weight of thecomposition. The upper limit is based on the requirement to have atleast the specified minimum quantities of other components. Beyond theupper limit, it may become difficult to adjust the pH or tonicityappropriately. The lower limit is based on the balance required when theother components are at their maximum. Furthermore, the lower limit ischosen so that the composition is not a sludge that would be difficultto pass through the needle used for injection. Also, below the lowerlimit, is may be more difficult to obtain a homogenous composition. Insome embodiments, the amount of carrier added is 60-80% by weight of thecomposition. In some embodiments, the amount of carrier added is 65% or80% by weight of the composition. The carrier may, but not always, formthe majority of the injectable composition. The carrier needs to becompatible with the blood plasma, avoid irritation on injection, becapable of aseptic processing, as well as completely solubilize theformulation, and thus prevent the formation of precipitation in theformulation.

B3. Antioxidant or Preservative

The antioxidant or preservative is present in the composition in aconcentration of 0-5% by weight of the composition. The antioxidant orpreservative provides chemical and/or anti-microbial stability to thecomposition so that it has a longer shelf life compared to compositionswithout the antioxidant or preservative. The amount of antioxidant orpreservative should be added in sufficient quantity to provide stabilityto the composition.

In some embodiments, the antioxidant or preservative is individuallychosen from or is a mixture of any of benzyl alcohol, ascorbic acid,methylparaben, propylparaben, benzalkonium chloride, thiomersal, sodiumbisulfite, sodium meta bisulfite, and thiourea.

The particular choice of antioxidant or preservative should becompatible with the selected carrier. For example, ascorbic acid willonly be soluble in polar solvents.

B4. Tonicity Modifier

In some embodiments, the composition includes a tonicity modifier. Eachcomponent may affect the tonicity of the composition. The tonicitymodifier is chosen to bring the tonicity of the composition in line withthat of human plasma. The tonicity modifier is chosen to be compatiblewith the other components of the composition to avoid precipitation. Thetonicity modifier is individually selected from or is a combination ofany of sodium carboxymethyl cellulose, acacia, gelatin, methyl celluloseand polyvinyl pyrrolidone.

B5. pH Modifier

Optionally, in some embodiments, the composition includes a pH modifieror pH buffer. The formulation of the composition needs to be acidicwith, for example, a pH of 4.5-5.5. This is due to the instability ofpsilocin at a pH of over 5.5. In some embodiments, the pH of thecomposition is 5. The pH of injectable drugs is usually about 7.5 or asclose as possible to this. The amount of pH modifier may make up to 10%by weight of the composition. The pH modifier (or pH buffer) includesone or a mixture of any of acetate, ammonium sulfate, ammoniumhydroxide, arginine, aspartic acid, benzene sulfonic acid, sodiumbenzoate, benzoic acid, sodium bicarbonate, boric acid, sodium borate,sodium carbonate, carbon dioxide, citric acid, sodium citrate, trisodiumcitrate, disodium citrate, diethyanolamine, glucono delta lactone,glycine, histidine, hydrochloric acid, hydrobromic acid, lysine, maleicacid, maglumine, methanesulfonic acid, monoethanolamine, phosphoricacid, monobasic potassium phosphate, dibasic potassium phosphate,tribasic sodium phosphate, dibasic sodium phosphate, monobasic sodiumphosphate, sodium hydroxide, sodium succinate, disodium succinate,sulfuric acid, tartaric acid, sodium tartrate and tromethamine (TRIS).

B6. Bioavailability Enhancer

Optionally, in some embodiments, the composition includes abioavailability enhancer. Bioavailability enhancers bind to activepharmaceutical ingredients and either increase their stability, abilityto cross membranes, or prevent the body from breaking down the API. Inone embodiment, the bioavailability enhancer is present in thecomposition in a concentration ranging up to 5% by weight of thecomposition. In another embodiment, the bioavailability enhancer ispresent in the composition in a concentration ranging from 0.5-2% byweight of the composition. Utilization of bioavailability enhancers inthese relatively small concentrations decreases the occurrence of anadverse effect, and only small concentrations are needed to beeffective. Examples of bioavailability enhancer include, but are notlimited to, beta cyclodextrin, alpha cyclodextrin, piperine, citricacid, and beta-carbolines (MAOI) such as harmaline.

The particular choice of bioavailability enhancer should be made basedon its compatibility with the carrier. Bioavailability enhancers maywork by different mechanisms. For example, all of them except the betacarbolines work by chelating. For example, chelation with citric acid isused to increase the bioavailability psilocin by protecting it fromoxidation in the body. The beta carbolines will prevent or reducebreakdown of psilocin in vivo. MAOIs prevent the body from breaking downtryptamines, and increase the concentration and duration of activity.

C. Extraction with Dephosphorylation Control

In one embodiment, referring to FIG. 1, a process for obtaining apsychoactive alkaloid extract with dephosphorylation control, accordingto an embodiment of the present invention, is shown. Dephosphorylationapplies to the psychoactive alkaloids that are phosphorylatable.

The process includes step 10 of obtaining powdered biomass from apsychoactive alkaloid source, such as a psychoactive organism. Thepowdered biomass is obtained by drying and pulverizing the psychoactivealkaloid source. The drying is carried out via vacuum desiccation,freeze drying, timed forced air drying, or other suitable drying methodknown to a person of skill in the art, to obtain a dried biomass. Thepulverization is carried out by milling, grinding, or other method toreduce the particle size of the dried biomass.

In one embodiment, the drying is carried out in a forced air ovencompletely shielded from all light at 20-30° C. for a time period of5-10 hours. However, there is room for optimization of the drying step,using different temperatures (e.g. 10-50° C.) and different durations.

In some embodiments, the psychoactive alkaloid source is a mushroom fromthe genus Conocybe, Copelandia, Galerina, Gymnopilus, Inocybe,Panaeolus, Pholiotina, Pluteus or Psilocybe, or any combination ofmushrooms selected therefrom. In some embodiments, gills, caps, stems,or the whole of the fungi is used as the alkaloid source. In otherembodiments, the psychoactive alkaloid source is another organism, suchas another fungus, a plant or an animal.

Step 12 involves extracting the psychoactive alkaloid from the driedpowdered biomass with an acidified solvent or a basified solvent toobtain a psychoactive alkaloid liquid with a specific pH, wherein thespecific pH is 3.5 or lower, or 10.5 or higher.

When used, the acid in step 12 may be acetic acid, adipic acid, ascorbicacid, ammonium aluminum sulphate, ammonium citrate dibasic, ammoniumcitrate monobasic, calcium citrate, calcium fumarate, calcium gluconate,calcium phosphate dibasic, calcium phosphate monobasic, hydrochloricacid, sulphuric acid monobasic, calcium phosphate tribasic, citric acid,fumaric acid, gluconic acid, magnesium fumarate, malic acid, phosphoricacid, potassium acid tartrate, potassium citrate, potassium fumarate,sodium citrate, sodium fumarate, sodium gluconate, sodium lactate,sodium potassium hexametaphosphate, sodium potassium tartrate, sodiumpotassium tripolyphosphate, sodium pyrophosphate tetrabasic, sodiumtripolyphosphate, tartaric acid, and any combination of one or more ofthese. In some embodiments, the acid is either only hydrochloric acid oronly phosphoric acid, for example. It is also envisaged that other acidsmay be used, for example non-food-grade acids that may be used bypharmaceuticals.

When used, the base in step 12 may be ammonium bicarbonate, ammoniumcarbonate, ammonium hydroxide, calcium acetate, calcium carbonate,calcium chloride, calcium hydroxide, calcium lactate, calcium oxide,calcium phosphate dibasic, calcium phosphate monobasic, magnesiumcarbonate, potassium aluminum sulphate, potassium bicarbonate, potassiumcarbonate, potassium hydroxide, potassium lactate, potassium phosphatedibasic, potassium pyrophosphate tetrabasic, potassium phosphatetribasic, potassium tripolyphosphate, sodium acetate, sodium acidpyrophosphate, sodium aluminum phosphate, sodium aluminum sulphate,sodium bicarbonate, sodium bisulphate, sodium carbonate, sodiumhexametaphosphate, sodium hydroxide, sodium lactate, sodium phosphatedibasic, sodium phosphate monobasic, sodium phosphate tribasic or anycombination selected therefrom. In one embodiment, the base is solelysodium hydroxide, for example. Other bases may be used in otherembodiments, for example non-food-grade bases that may be used bypharmaceuticals.

In some embodiments, the acidified solvent is a mixture of an acid and aC1-C4 primary aliphatic alcohol, a C3-C4 ketone, water, or anycombination selected therefrom, for example. The acid may be citricacid, ascorbic acid, formic acid, acetic acid, hydrochloric acid,phosphoric acid, sulphuric acid, or any combination selected therefrom,for example. In other embodiments, the basified solvent is a mixture ofa base and a C1-C4 primary aliphatic alcohol, a C3-C4 ketone, water, orany combination selected therefrom. The base may be sodium hydroxide,potassium hydroxide, ammonium hydroxide, sodium bicarbonate, calciumcarbonate, or any combination selected therefrom.

After adding the acidified solvent, if the acidified solvent used, thepsychoactive alkaloid liquid has a pH ranging from 0.5-3.5. In anexemplary embodiment, the pH of the psychoactive alkaloid liquidobtained after addition of the acidified solvent is 2. The pH isadjusted to lower than 3.5 in the extraction step 12 to promote theconversion of phosphorylated psychoactive alkaloid to dephosphorylatedpsychoactive alkaloid, thus allowing the preparation of the psychoactivealkaloid liquid with the predominantly or entirely dephosphorylatedpsychoactive alkaloid. For example, with pH conditions lower than 3.5,psilocybin is readily converted to psilocin. In some embodiments, duringthe extraction step the psychoactive alkaloid liquid has a pH lower than3.5 and the desired amount of the phosphorylated psychoactive alkaloidis 0% by weight of the total psychoactive alkaloid content in thepsychoactive alkaloid extract. The desired amount of thedephosphorylated psychoactive alkaloid is 100% by weight of the totalpsychoactive alkaloid content in the psychoactive alkaloid extract. Evenwith neutral hydroethanol extraction, a large portion of psilocybin maybe converted to psilocin. However, the low pH environment (<3.5)protects the psilocin from oxidation.

If the pH in step 12 were 10.5 or higher, then the conversion ofphosphorylated alkaloids to dephosphorylated alkaloids would beinhibited, and the result would be predominantly or entirelyphosphorylated alkaloids. This may be limited by the initial amount ofalkaloids in the psychoactive alkaloid source that were alreadydephosphorylated. As predominantly dephosphorylated alkaloids are moreuseful in the injectable composition than phosphorylated alkaloids, thenthe acidified solvent would be chosen in step 12.

In some embodiments, the extraction is performed at a temperatureranging from 5-95° C. In other embodiments, the extraction is performedat a temperature ranging from 50-75° C. In other embodiments, theextraction is performed at room temperature.

In some embodiments, the extraction is performed for a time periodranging from 10-720 minutes. For most cases, a time below 10 min wouldresult in a mostly incomplete yield, and above 720 min the extractionmay be incomplete but would be continuing at a negligible rate. Inanother embodiment, and more usually, the extraction is performed for atime period ranging from 30-240 minutes.

In some embodiments, the extraction is performed at an applied pressureranging from 50 kPa to 140 MPa (7 to 20,000 psi). In yet anotherembodiment, the extraction is performed at a pressure ranging from 70kPa to 140 kPa (10 to 20 psi). Application of pressure may be used toincrease the rate of extraction.

In some embodiments, the extraction is performed with a solvent to solidratio in the range 1 L:1 kg to 50 L:1 kg, wherein the solid is the driedpowdered biomass. In one embodiment, the extraction is performed with asolvent to solid ratio of 20 L:1 kg.

After the addition of the acidified solvent or the basified solvent, thepowered biomass and the solvent may be mixed, continually orintermittently during the extraction, followed by step 14 of filtrationto result in an extracted filtrate (i.e. psychoactive alkaloid liquid).

In step 18 of the process, the pH of the obtained psychoactive alkaloidliquid is adjusted to a pH ranging from 3.5-4.5. The pH is adjusted byadding a base or an acid. The pH is adjusted to a value in this range asthe psychoactive alkaloid liquid exhibits a good anti-microbialstability in this pH range. Also, there is no conversion (or furtherconversion, as the case may be) of phosphorylated alkaloids todephosphorylated alkaloids at this pH after the alkaloids are removedfrom the biomass, which points to enzymatic hydrolysis being responsiblefor conversion in the source of the psychoactive alkaloids. In exemplaryembodiments for step 18, the base is sodium hydroxide and the acid iscitric acid. Any other appropriate acid or base can be used to adjustthe pH, which a person of skill in the art may determine. The selectionof the acid or the base will depend upon the nature of the pH of thepsychoactive alkaloid liquid prior to adjusting it to the range of4.5-5.5.

In some embodiments, the extraction includes further extracting thepsychoactive alkaloid by repeating the extraction step. Filtrate residuefrom step 14 is collected and to this filtrate residue, the same or adifferent acidified solvent, or the same or a different basified solventis added, as in step 12. The resulting mixture is mixed and followed byfiltration to obtain another filtrate. This filtrate and the previousfiltrate are mixed together to result in a bulk or pooled filtrate. Tothis bulk filtrate the acid or the base is added to adjust the pH to4.5-5.5 according to step 18. In some embodiments, the furtherextraction of the filtrate obtained after extraction with the acidifiedor the basified solvent is repeated until a required amount of thephosphorylated psychoactive alkaloid and/or the dephosphorylatedpsychoactive alkaloid is extracted. The number of extraction cycles tobe repeated will depend on various variable factors such as the sourceof the psychoactive alkaloid and the solubility of the psychoactivealkaloid in the acidified or the basified solvent.

Step 20 of the process involves evaporating the solvent from thepsychoactive alkaloid liquid (i.e. the filtrate or bulk filtrate) toobtain the psychoactive alkaloid extract with the desired amount of thephosphorylated psychoactive alkaloid and the desired amount of thedephosphorylated psychoactive alkaloid. The solvent is completely orpartially evaporated to result in the psychoactive alkaloid extract as aslurry or powder. The evaporation is carried out by methods such asair-drying, rotary evaporation, or other methods known in the art tosuitably evaporate solvent from psychoactive alkaloid liquid. At thispoint in time, away from the biomass, dephosphorylated andphosphorylated alkaloids are fairly heat resistant, more so undervacuum, and so rotary evaporation, for example, is a suitable process.

Evaporation step 20 may be paused, for standardization in step 21, andcontinued after standardization. The evaporation of a portion of thesolvent, before collection of the psychoactive alkaloid extract, inslurry form, for standardization, is done to obtain a quantity of apsychoactive alkaloid extract slurry that is easy to handle in thesubsequent steps of the standardization process. The quantity of theportion of the solvent to be evaporated before pausing the evaporationis not so much as to make it too viscous to handle well. The quantity ofthe portion of the solvent to be evaporated will depend on variousfactors, for example, but not limited to, the contents of thepsychoactive alkaloid liquid and the quantity of the psychoactivealkaloid liquid present at the beginning of the evaporation step.

For the purposes of the injectable composition disclosed herein, thedesired amount of the dephosphorylated psychoactive alkaloid isgenerally chosen to be 100% of the total phosphorylatable psychoactivealkaloid content in the psychoactive alkaloid extract, and the desiredamount of the phosphorylated psychoactive alkaloid is 0%. As such, anacidified solvent is selected in step 12. However, it is conceivablethat an injectable composition with 100% or predominantly phosphorylatedpsychoactive alkaloids may be made for the purposes of study or otheruses, in which case a basified solvent is chosen in step 12. A mixtureof a 100% dephosphorylated extract with a 100% phosphorylated extractcan be made to result in an extract with any desired ratio ofphosphorylated to dephosphorylated psychoactive alkaloids.

D. Purification

In one embodiment, referring to FIG. 2, steps of a process for obtaininga purified psychoactive alkaloid extract are shown. The main steps are:adsorbing, in step 34, the psychoactive alkaloid extract obtained instep 18 or 20 (without standardization) in solution onto a resin toobtain an adsorbed psychoactive alkaloid, which may include one or moreadsorbed psychoactive alkaloids; eluting, in step 38, the adsorbedpsychoactive alkaloid using a solvent to obtain a purified psychoactivealkaloid solution; and evaporating, in step 42, the solvent from thepurified psychoactive alkaloid solution.

In one embodiment, the psychoactive alkaloid extract obtained in step 18or 20 is followed by completely or partially concentrating the obtainedpsychoactive alkaloid extract by evaporation of the solvent from theextract in step 22, if the solvent is not already fully evaporated. Ifthe solvent from the extract has been completely evaporated in step 22,then reverse osmosis water, more solvent or another solvent is addedback. Other water may be used in place of reverse osmosis water, whichis usually selected for its purity.

In some embodiments, the process includes adding, in step 26, an acid ora base to the psychoactive alkaloid extract obtained in step 20 toobtain a psychoactive alkaloid solution with a desired pH.

When used, the acid may be acetic acid, adipic acid, ascorbic acid,ammonium aluminum sulphate, ammonium citrate dibasic, ammonium citratemonobasic, calcium citrate, calcium fumarate, calcium gluconate, calciumphosphate dibasic, calcium phosphate monobasic, hydrochloric acid,sulphuric acid monobasic, calcium phosphate tribasic, citric acid,fumaric acid, gluconic acid, magnesium fumarate, malic acid, phosphoricacid, potassium acid tartrate, potassium citrate, potassium fumarate,sodium citrate, sodium fumarate, sodium gluconate, sodium lactate,sodium potassium hexametaphosphate, sodium potassium tartrate, sodiumpotassium tripolyphosphate, sodium pyrophosphate tetrabasic, sodiumtripolyphosphate, tartaric acid, and any combination of one or more ofthese. In some embodiments, the acid is either only hydrochloric acid oronly phosphoric acid, for example. It is also envisaged that other acidsmay be used.

When used, the base may be ammonium bicarbonate, ammonium carbonate,ammonium hydroxide, calcium acetate, calcium carbonate, calciumchloride, calcium hydroxide, calcium lactate, calcium oxide, calciumphosphate dibasic, calcium phosphate monobasic, magnesium carbonate,potassium aluminum sulphate, potassium bicarbonate, potassium carbonate,potassium hydroxide, potassium lactate, potassium phosphate dibasic,potassium pyrophosphate tetrabasic, potassium phosphate tribasic,potassium tripolyphosphate, sodium acetate, sodium acid pyrophosphate,sodium aluminum phosphate, sodium aluminum sulphate, sodium bicarbonate,sodium bisulphate, sodium carbonate, sodium hexametaphosphate, sodiumhydroxide, sodium lactate, sodium phosphate dibasic, sodium phosphatemonobasic, sodium phosphate tribasic or any combination therefrom. Inone embodiment, the base is solely sodium hydroxide, for example. Otherbases may be used in other embodiments.

In one embodiment, the process includes adding phosphoric acid to thepsychoactive alkaloid extract to achieve a pH of 4. In anotherembodiment, the process includes adding hydrochloric acid to thepsychoactive alkaloid extract to achieve a pH of 3. In yet anotherembodiment, the process includes adding sodium hydroxide to thepsychoactive alkaloid extract to achieve a pH of 9.5.

The process includes, in step 30, optionally filtering, centrifuging, orclarifying the psychoactive alkaloid solution or desired pH psychoactivealkaloid solution, as the case may be, and utilizing the obtainedfiltrate for the following step of adsorption. Clarifying may beperformed, for example, by adding an agglomeration agent. In step 34,the process involves adsorbing the psychoactive alkaloid(s) in thesolution onto the resin to obtain an adsorbed psychoactive alkaloid.This may be done, for example, by contacting the psychoactive alkaloidsolution with the resin or otherwise treating the psychoactive alkaloidsolution with the resin.

In some embodiments, the resin used in step 34 is an adsorbent resin ofthe macroporous type, such as, a cation or anion ion-exchange resin, anon-ionic resin, or any combination therefrom. Representativepharmaceutical, nutraceutical or food-grade grade resins for use inaccordance with the present invention are known to those skilled in theart. For example, pharmaceutical grade non-ionic macroporous resins arecommercially available, e.g. Amberlite® XAD4. In some embodiments, theresin is a cationic ion-exchange resin or an anionic-exchange resin. Thecationic ion-exchange resin may be selected from commercially availablecationic ion-exchange resins known in the art, including but not limitedto Amberlite® MAC-3 H. The cationic ion-exchange resin may be in an H⁺form or an Na⁺ form. The anionic ion-exchange resin may be selected fromcommercially available anion exchange resins known in the art, includingbut not limited to Amberchrom® 50WX8. The anionic ion-exchange resin maybe in an OH⁻ form or a Cl⁻ form. The resins used may be of any particlesize. In some embodiments, the resins may be gel type resins, with anysize of gel bead.

In step 36, the process involves washing the resin to remove adsorbedimpurities from the resin. While not all the impurities are adsorbedonto the resin, some of them may be. The washing step, substantially,does not remove the adsorbed psychoactive alkaloids. The washing solventmay be 100% ethanol, 100% reverse osmosis water, or any other washingsolvent used in ion-exchange resin chromatography, provided that thewashing removes impurities or by-products that are adsorbed on theresin. Impurities or by-products may include, for example, sugars,carbohydrates, chitin, chitosan, fats, minerals, waxes, or proteins.There may be one, two or more washing steps depending on the embodiment,and the same or different washing solvents may be used for each wash. Inother embodiments, the solvent(s) for washing may include a primaryaliphatic alcohol, a ketone, water, and any combination therefrom. Inone embodiment, the primary aliphatic alcohol is a C1-4 alcohol. In oneembodiment, the primary aliphatic alcohol is 5% ethanol. In oneembodiment, the primary aliphatic alcohol is ethanol. In one embodiment,the ketone is a C3-4 ketone. In yet another embodiment, the water isselected from deionized, distilled, reverse osmosis, or otherwisepurified water that is substantially without free ions.

After the washing, the process involves eluting, in step 38, theadsorbed psychoactive alkaloid from the resin using a solvent to obtaina purified psychoactive alkaloid solution. The solvent may be an organicsolvent, an acid, a base, or water, a combination of an organic solventand a base, or a combination of an organic solvent and an acid, acombination of an organic solvent and water, a combination of water anda base, or combination of water and an acid. The result of the elutionstep is a purified psychoactive alkaloid solution. Usually, the solventis different from the solvent in which the extract is initiallyprovided, and is either a different type of solvent or a differentcomposition of solvent. It may be at a different temperature than theinitial solvent.

In some embodiments, the solvent used in the elution step 38 may be aprimary aliphatic alcohol, a ketone, water, and any combinationtherefrom. In one embodiment, the primary aliphatic alcohol is a C1-4alcohol. In one embodiment, the primary aliphatic alcohol is 5% ethanol.In one embodiment, the primary aliphatic alcohol is ethanol. In oneembodiment, the ketone is a C3-4 ketone. In yet another embodiment, thewater is deionized, distilled, reverse osmosis, or otherwise purifiedwater, which is substantially without free ions. In other embodiments,the water is not purified.

In one embodiment, the solvent used in the elution step 38 is acombination of an organic solvent and an acid. In one embodiment, thecombination of an acid and an organic solvent is 2% hydrochloric acidand 80% ethanol, for example. In general, any acidic environment willdisplace some of the ions from the resin, but the rate and optimizationof desorption will be affected by the acid concentration. In oneembodiment, the solvent used in the elution step 38 is a combination ofan organic solvent and a base. In one embodiment, the combination of anorganic solvent and a base is of 2% sodium chloride and 80% ethanol, forexample. In general, any basic environment will displace some of theions from the resin, but the rate and optimization of desorption will beaffected by the concentration of the base.

All the above solvents and combinations thereof are suitable for theelution step because all of the psychoactive alkaloids of interest aresoluble therein and, depending on the choice of resin, they are allcapable of pulling the alkaloids of interest off a resin. There are manydifferent resins available, and it is a straightforward matter to selecta suitable resin and elution solvent pair.

In one embodiment, the elution step is carried out at a temperature inthe range of 4-75° C. These temperatures are limited by the boilingpoint of the solvent used, as well as the specifications of allowablefood-grade resins, as determined by the manufacturers of the resins andgovernmental food and drug administrations. In another embodiment, theelution step is carried out at room temperature for convenience, i.e. at21-25° C.

Optionally, the purified psychoactive alkaloid solution obtained afterelution is further purified by filtering, in step 39, the obtainedpurified psychoactive alkaloid solution to obtain a filtrate, and thenrepeating at least steps 34 and 38 with the obtained filtrate. Steps 34and 38 can be repeated with the same or a different resinous materialand the same or a different solvent to obtain a further ortwice-purified psychoactive alkaloid solution.

The result of the elution is a purified psychoactive alkaloid solution.In one embodiment, the purified psychoactive alkaloid solution has aconcentration of 0.07% by weight of a psychoactive alkaloid, which isthe concentration before removal of some or all of the solvent. Thisconcentration may be different in other embodiments, depending on theamount solvent used for the elution and the potency of the rawmaterials. In one embodiment, the purified psychoactive alkaloidsolution is concentrated by evaporating the solvent to form a purifiedpsychoactive slurry that has at least of 5% by weight or more ofpsychoactive alkaloid. In another embodiment, the resulting purifiedpsychoactive alkaloid slurry has 5-68% by weight of psychoactivealkaloid. In yet other embodiments, the purified psychoactive alkaloidslurry has a concentration of psychoactive alkaloid outside theseranges, and, when dried, can be as low as 0.1% or as high as 99% drywt/wt %.

Following the elution, a further washing step 40 may be employed using100% ethanol, for example, to wash the resin. This may be considered tobe a cleaning step, to refresh the resin and make it ready to be usedagain in a subsequent step or in another process. In other embodiments,the solvent for further washing may be a primary aliphatic alcohol, aketone, water, and any combination therefrom. In one embodiment, theprimary aliphatic alcohol is a C1-4 alcohol. In one embodiment, theprimary aliphatic alcohol is 5% ethanol. In one embodiment, the ketoneis a C3-4 ketone. In yet another embodiment, the water is selected fromdeionized, distilled, reverse osmosis, or otherwise purified water thatis substantially without free ions.

After elution step 38, the obtained purified psychoactive alkaloidsolution undergoes the evaporation step 42 to completely or partiallyevaporate the solvents and result in the purified psychoactive alkaloidextract (slurry or powder form).

Step 42 involves evaporating the solvent from the purified psychoactivealkaloid solution to obtain the purified psychoactive alkaloid extractwith, if dephosphorylation control has been used, the desired amount ofthe phosphorylated psychoactive alkaloid and the desired amount of thedephosphorylated psychoactive alkaloid (for example, 0% and 100%respectively for the composition herein). The solvent is completely orpartially evaporated to result in the psychoactive alkaloid extract(slurry or powder respectively). The evaporation is carried out bymethods such as air-drying, rotary evaporation, or other methods knownin the art to suitably evaporate solvent from psychoactive alkaloidliquid.

Evaporation in step 42 may be paused, for standardization in step 43,and continued after standardization. The evaporation of a portion of thesolvent, before collection of the purified psychoactive alkaloid slurryfor standardization, is done to obtain a quantity of a psychoactivealkaloid slurry that is easy to handle in the subsequent steps of thestandardization process. The quantity of the portion of the solvent tobe evaporated before pausing the evaporation is not so much as to makeit too viscous to handle well. The quantity of the portion of thesolvent to be evaporated will depend on various factors, for example,but not limited to, the contents of the psychoactive alkaloid solutionand the quantity of the psychoactive alkaloid solution present at thebeginning of the evaporation step.

E. Standardization

Standardization may be carried out part way through evaporation step 20(FIG. 1) or evaporation step 42 (FIG. 2), or it may be done before orafter either of these steps. Standardization is more conveniently donewhen the extract is a slurry than a powder, but it is not necessary thatit is a slurry. Firstly, for example for a slurry, the weight percentageof the psychoactive alkaloids in the psychoactive alkaloid extract andthe weight proportion of solids in the psychoactive alkaloid extract aremeasured. The psychoactive alkaloid content in the final composition isspecified. A measured amount of one or more excipients is added to thepsychoactive alkaloid extract, such that, when the remaining solvent isevaporated, the resultant solid will have the specified content ofpsychoactive alkaloids. The specific amount of the total psychoactivealkaloid content in the standardized extract may be accurate to one ortwo decimal places, or one or two significant figures depending on howaccurately the measurements are made during the mixing of thepsychoactive alkaloid extract and the one or more excipients. Theexcipients used in standardizing the extract may be, for example, one ormore of the excipients that are in the final injectable composition,such as a tonicity modifier or an antioxidant.

Standardization results in a standardized, extracted psychoactivealkaloid composition or a standardized psychoactive alkaloid extract.The standardized psychoactive alkaloid extract obtained has a specificamount of total psychoactive alkaloid content. Further, the psychoactivealkaloid is made up of a psychoactive alkaloid with a controlled amountof dephosphorylation, and possibly other psychoactive alkaloids that arenot dephosphorylatable.

In other embodiments, the standardization process occurs at the time ofpreparation of the injectable composition, in FIG. 3. This is done byselecting the quantities of excipients and psychoactive component sothat the final, injectable composition has the specified concentrationof psychoactive alkaloids.

F. Preparation of Composition

In some embodiments, referring to FIG. 3, the key steps of a process forforming an injectable psychoactive alkaloid composition are shown.

Step 44 involves mixing the carrier with the purified psychoactivealkaloid extract and the antioxidant until the mixture is homogenous.Then, the tonicity modifier is added to the mixture and mixed until themixture is homogenous in step 46. The order of mixing helps thehomogenization of the mixture and prevents the mixture from forminglayers during the process. A person of skill in the art will appreciatethat the mixing steps can be performed by any suitable methods, which donot cause any damage to the active pharmaceutical ingredients or theexcipients, as known in the literature. The pH is then brought at avalue between 4.5-5.5 by adding a pH buffer to the mixture, in step 48.In some embodiments, the pH of the obtained psychoactive alkaloidcomposition is adjusted to a pH of 5±0.25. The pH of injectable drugs isusually about 7.5. The chosen pH range of the psychoactive alkaloidcomposition is therefore close enough to the conventional range of thepH for injectable drugs. Once prepared, the composition is then sterilefiltered, in step 49.

Finally, the mixture is ready to be packaged and stored, in step 50. Insome embodiments, the mixture is stored in glass jars or vials at atemperature between 4-30° C., and in complete darkness.

G. Examples

In order to further illustrate the present invention, the followingspecific examples are given with the understanding that these examplesare intended only to be illustrations without serving as a limitation onthe scope of the present invention. All parameters, dimensions,materials, quantities and configurations described herein are examplesonly and may be changed depending on the specific embodiment. Theprocess may be scaled up using larger quantities and modified apparatus.

Although the examples of the present invention have been formulatedspecifically using Psilocybe cubensis as a source to obtain apsychoactive alkaloid extract, the extract comprising predominantlydephosphorylated psychoactive alkaloid (e.g. psilocin), other sourcesare possible. A person skilled in the art would appreciate that thePsilocybe cubensis can be readily substituted by other sources ofpsychoactive alkaloids to obtain a variety of psychoactive alkaloidshaving similar properties, such psilocybin, baeocystin, norbaeocystin,aeruginascin, psilocin, norpsilocin, 4-hydroxytryptamine,N,N,N-trimethyl-4-hydroxytryptamine, or any combination therefrom, toname a few, to result in compositions with similar efficacy andefficiency as well. For example, mushrooms from the genus Conocybe,Copelandia, Galerina, Gymnopilus, Inocybe, Panaeolus, Pholiotina,Pluteus, Psilocybe, or any combination therefrom may be used.

Example 1: Extraction Process with Promotion of Dephosphorylation

2.5 kilograms of Psilocybe cubensis were dried in a forced air oven at25° C. for 10 hours to result in 140 grams of dried biomass. The driedbiomass was then pulverized to a size of 200 mesh with a hammer mill.

An acidified solvent, i.e. a pH-adjusted, hydro-ethanol mixture, wasprepared. 144 g of anhydrous citric acid was placed into a 5 L vesselwith 1.25 L of reverse osmosis water, followed by the addition of 3.75 Lof ethanol. The contents were mixed until completely dissolved. Anacidified solvent with a pH of 2 was obtained.

The dried powdered biomass was placed into an agitated, heat-controlledvessel with 5 L of the acidified solvent and mixed for the extraction ofpsychoactive alkaloid. The extraction was controlled to a constant 75°C., and the duration of extraction was 1 hour. The extraction slurry wasthen filtered. Filtration resulted in a filtrate, i.e. the psychoactivealkaloid liquid, and a filter residue. The filter residue was placedback into the extraction vessel and extracted with an additional 5 L ofthe acidified solvent. The temperature of extraction was again 75° C.and the time was 1 hour. The extraction slurry was filtered. Thefiltrates from the first and second extraction were mixed to form 10 Lof mixed filtrate. The pH of the mixed filtrate was then increased with5 M sodium hydroxide until a pH of 4.5 was achieved. Immediately afteradjusting the pH, the mixed filtrate was placed into a rotary evaporatorat 50° C. and 250 torr, and the solvent was partially evaporated toobtain a psychoactive alkaloid extract.

Final stages of evaporation were performed using a freeze dryer, andthen the psychoactive alkaloid extract was obtained. When dried to apowder, the psychoactive alkaloid extract had a total psychoactivealkaloid concentration of 0.86% by weight of the psychoactive alkaloidextract. Further, the desired amount of the phosphorylated psychoactivealkaloid obtained was 0.00% by weight of the total psychoactive alkaloidcontent in the psychoactive alkaloid extract. The desired amount of thedephosphorylated psychoactive alkaloid obtained was 100% by weight ofthe total psychoactive alkaloid content in the psychoactive alkaloidextract.

Example 2.1: Purification with a Non-Ionic Macroporous Resin

The pH of the psychoactive alkaloid extract of example 1, in aqueousform, was adjusted to pH 4.0 (+/−0.5) by adding 2 M phosphoric acid andcentrifuged for 15 minutes at 3000 g to remove any solid precipitate.The pH of 4 corresponds to the isoelectric point of psilocybin, andpsilocin's polarity is such that it is partitioned onto the resin, thusallowing effective binding of the psychoactive alkaloids psilocybin (ifpresent, i.e. dephosphorylation is not used or is incomplete) andpsilocin to the macroporous resin. Norbaeocystin and baeocystin arephosphorylated and if present would behave in the same way aspsilocybin. The supernatant obtained was loaded onto a column ofAmberlite® XAD4, a non-ionic macroporous resin (50.34 g of dry resin) ata flow rate of 2 bed volumes per hour, to allow components in thesupernatant to be adsorbed onto the macroporous resin. After all 2.5 Lof the extract was loaded onto the column of macroporous resin, thecolumn was washed in a single pass with 5 bed volumes of reverse osmosiswater at room temperature. This was followed by elution with 5 bedvolumes of 5% ethanol (by weight), again at room temperature. Finally,the column was washed in a single pass with 5 bed volumes of 100%ethanol. The elution was performed at room temperature. Each of thesethree fractions was collected separately. The particular order for thewashing steps and the elution was selected to be in the order of thepolarity of the solvents. If the order were different, an inferiorresult may have ensued, such as a lower yield. The first fraction usingreverse osmosis water removed the most polar compounds from the resin.The hydroethanol fraction eluted compounds of lesser polarity, and the100% ethanol solvent removed the least polar compounds. Less polarsolvents could also be used to elute less polar compounds.

The 5% ethanol fraction (i.e. the purified psychoactive alkaloidsolution) was then concentrated in a rotary evaporator to form 3.90 g ofconcentrated aqueous slurry at 30% solids, containing 195.1 mg of totalalkaloids (e.g. psilocin and possibly other dephosphorylatedpsychoactive alkaloids). The result was a purified psychoactive alkaloidextract, in slurry form. Further, the desired amount of the psychoactivealkaloid obtained was 5.00% by weight of the slurry. Knowing this, it ispossible to replace the solvent with an equivalent weight of excipientsto provide a purified extract with a psychoactive alkaloid content of5.00% dry weight. A greater or lesser amount of excipients will result,respectively, in a lower or higher psychoactive alkaloid content.

A similar process may be used for purification of extracts that havebeen obtained without the dephosphorylation control.

Example 2.2: Purification with Cation Exchange and Non-Ionic MacroporousResins

The pH of the psychoactive alkaloid extract of example 1, in aqueousform, was adjusted to a pH of 3.0 (+/−0.5) by adding 1M HCl. It was thenmixed with 200 g of Amberlite® MAC-3 H, a strong cationic ion-exchangeresin in its hydrogen form, to result in a filtrate-resin mixture, inwhich components of the psychoactive alkaloid filtrate were adsorbedonto the cation exchange resin. Psilocin's polarity is such that it ispartitioned onto the resin. The pH of 3 would also ensure thatpsilocybin, if present, was in its protonated form, and thus alsoadsorbed onto the cationic exchange resin efficiently. Thefiltrate-resin mixture was agitated for 4 hours at room temperature (21°C.-25° C.) and then filtered. The filtrate was discarded, and the resinwas rinsed with 2.0 L of 100% EtOH and then 2.0 L of H₂O to remove anyimpurities. Finally, the psilocin (and, in other cases, psilocybin)fraction was eluted with 2.0 L of 2% HCl/80% EtOH, for 4 hours at roomtemperature.

The eluted fraction was brought to a pH of 4.0 (i.e. the isoelectricpoint of psilocybin) by adding 2M NaOH. The filtrate was thencentrifuged at 3000 g to remove any solid precipitate. The resultantfiltrate, in form of an aqueous solution, was then placed into a rotaryevaporator and the solvent was removed until the aqueous solutionreached a volume of 400 mL. The aqueous solution was then againcentrifuged for 15 minutes at 3000 g to remove any solid precipitate.The supernatant was loaded onto a column of Amberlite® XAD4 macroporousresin (45.53 g of dry resin) at a flow rate of 2 bed volumes per hour.After all the 400 mL of the supernatant was loaded onto the column, itwas initially washed with 5 bed volumes of reverse osmosis water,followed by elution with 5 bed volumes of 5% ethanol (by weight) andthen washed with 100% ethanol. Each of these fractions was collectedseparately. The 5% ethanol fraction (i.e. the purified psychoactivealkaloid solution) was concentrated in a rotary evaporator to form 258mg of solution containing 175 mg of total psychoactive alkaloids (i.e.psilocin and other dephosphorylated psychoactive alkaloids). Thus, apurified psychoactive alkaloid extract, in slurry form, with a totalalkaloid concentration of 68% dry wt/wt % was obtained.

A similar process may be used for purification of extracts that havebeen obtained without the dephosphorylation control.

Example 2.3: Purification with Anion Exchange and Non-Ionic MacroporousResins

The pH of the psychoactive alkaloid extract of example 1, which was inaqueous form, was adjusted to 9.5 (+/−0.5) by adding 1 M NaOH and thenmixed with 150 g of Amberchrom® 50WX8 strong anionic ion-exchange resinin its hydrogen form to result in a filtrate-resin mixture, in whichcomponents of the psychoactive alkaloid filtrate were adsorbed onto theanion exchange resin. The pH of 9.5 (+/−0.5) ensured that thepsychoactive alkaloids (e.g. psilocin) were deprotonated and had a netnegative charge for efficient adsorption onto the strong anionexchanger.

The filtrate-resin mixture was agitated for 4 hours and then filteredout, and the filtrate was discarded. The resin was rinsed with 2.0 L of100% EtOH and then 2.0 L of H₂O to remove impurities. Finally, thepsychoactive alkaloid fraction was eluted with 2.0 L of 2% NaCl/80% EtOHfor 4 hours.

The eluted fraction was brought to a pH of 4.0 with the addition 2 MHCl. The extract was then centrifuged at 3000 g to remove any solidprecipitate. The resultant extract, in from of a solution, was thenplaced into a rotary evaporator and the solvent was removed to result ina volume of 400 mL.

The resultant 400 mL aqueous solution was centrifuged for 15 minutes at3000 g to remove any solid precipitate. The supernatant was loaded ontoa column of Amberlite® XAD4 macroporous resin (45.53 g of dry resin) ata flow rate of 2 bed volumes per hour, to allow components of thesupernatant to be adsorbed onto the macroporous resin. After all 400 mLof supernatant was loaded onto the column, the column was initiallywashed with 5 bed volumes of reverse osmosis water, followed by elutionwith 5 bed volumes of 5% ethanol (by weight) and then a final wash with100% ethanol was performed. Each of these fractions was collectedseparately. The 5% ethanol fraction (i.e. the purified psychoactivealkaloid solution) was concentrated in a rotary evaporator to form 325mg of solution containing 175 mg of total alkaloids (e.g. psilocin andother dephosphorylated psychoactive alkaloids). A purified psychoactivealkaloid extract, in slurry form, with a concentration of 54% dry wt/wt% of total alkaloids was therefore obtained.

A similar process may be used for purification of extracts that havebeen obtained without the dephosphorylation control.

Example 3.1: First Injectable Composition

The first example of the composition can be seen in TABLE 3, madeaccording to steps 44-46 of FIG. 3. A natural extract with 20.00% byweight of alkaloid content is chosen as the psychoactive component, andthis forms 10% of the composition. The carrier is a mixture of 60% byweight of H₂O and 20% by weight of PEG 300. The preservative is amixture of 2.5% by weight of ascorbic acid and 2.5% by weight of benzylalcohol. The tonicity modifier is 5% by weight of dextrose.

TABLE 3 Component Specified Ingredient/% Psychoactive synthetic orextract 10% extract Carrier 60% H₂O/20% PEG 300 Preservative 2.5%ascorbic acid; 2.5% benzyl alcohol Tonicity modifier 5% dextrose

Example 3.2: Second Injectable Composition

This further example can be seen in TABLE 4, and is prepared usingsimilar steps as for preparing example 3.1, with the additional step ofadding a pH modifier. A natural extract with 10.00% by weight ofalkaloid content is chosen as the psychoactive component, and this forms20% of the composition. The carrier is a mixture of 40% by weight of H₂Oand 25% by weight of glycerine. The preservative is 5% by weight ofmethylparaben. The tonicity modifier is 5% by weight of dextrose. Inthis composition, a pH modifier is included, which is 5% by weight ofcitric acid.

TABLE 4 Component Range/% Psychoactive synthetic or extract 20% extractCarrier 40% H₂O; 25% glycerine Preservative 5% methylparaben Tonicitymodifier 5% dextrose pH modifier 5% citric acid

H. Apparatus

FIG. 4 depicts an apparatus used for obtaining a psychoactive alkaloidextract and forming an injectable composition. In one example, rawPsilocybe cubensis mushrooms are added to a hopper 100 and then releasedin batches into container 102. The raw fungal material is then dried ina forced air oven 104 to result in the dried biomass. The dried biomassis placed into a grinder 106 for grinding to result in dried powderedbiomass.

The dried powdered biomass is then placed into a heat-controlled vessel110 and acidified solvent (S) added to the heat-controlled vessel toobtain a specific pH (e.g. lower than 3.5). The vessel 110 is surroundedby an insulating wall 108. Alternately, an insulating jacket may bewrapped around the vessel. The insulating wall 108 or jacket helps tomaintain the contents 112 under a constant temperature (T) between 5-95°C. The applied pressure (P) inside the extraction vessel 110 may beregulated from 50 kPa to 140 MPa (7 to 20,000 psi). The extraction maybe performed with a solvent to solid (dried powdered biomass) proportionin the range of 1 L:1 kg to 50 L:1 kg.

After the extraction, the bottom of the extraction vessel 110 may beopened at outlet 114 and the extraction slurry collected in a container120. The extraction slurry is then fed into a filter 122 and a firstfiltrate collected in container 124. The first filtrate residue 130 maythen be fed back (R) into the agitated, heat-controlled vessel 110 andmore solvent (S) added for a second extraction. After the secondextraction, the extraction slurry may be collected in the container 120and then fed into a filter 132. After filtration, the obtained secondfiltrate is collected in container 136.

After the two filtration stages, the filtrates are mixed in container140 to obtain a mixed filtrate i.e. the psychoactive alkaloid liquid. Inother embodiments, if there is only a single filtration step, thismixing step is not required. By adding a base to container 140, the pHof the psychoactive alkaloid liquid may be brought to a pH ranging from4.5-5.5.

The pH-adjusted, mixed filtrate is then placed in a rotary evaporator142 and part of the solvent evaporated from the mixed filtrate to formthe psychoactive alkaloid extract, which is here a slurry.

The resultant slurry is then transferred to a container 144 where ameasured quantity of one or more excipients is added to obtain astandardized psychoactive alkaloid composition in slurry form. Theobtained standardized slurry may then be then dried to obtain thestandardized psychoactive alkaloid composition.

In another example, a purified, standardized psychoactive compositionmay be obtained. The resultant slurry from the rotary evaporator 142 istransferred to the container 144, where the pH of the extract may beadjusted, followed by centrifugation 146 to remove the solidprecipitates.

The resultant supernatant is loaded onto a column 150 of resin. Aninitial wash is given to the column with a solvent to remove impuritiesfrom the resin, and fraction 154 is collected. A second wash is given tothe column with another solvent to elute the psychoactive alkaloids fromthe column and result in fraction 156. A final wash is given to thecolumn with another solvent to wash any impurities from the column, toprepare the column for use again, and the fraction 158 is obtained. Theelution fraction 156 with the psychoactive alkaloids is thenconcentrated in a rotary evaporator 160 to result in the purifiedpsychoactive alkaloid solution. The solvent from the purifiedpsychoactive alkaloid solution is then completely or partiallyevaporated to result in the purified psychoactive alkaloid extract 164.This extract may then be standardized by adding a measured amount ofexcipient to it and mixing, in container 166. If necessary, the mixturemay then be dried.

The standardized, purified psychoactive composition 166 or thestandardized psychoactive composition obtained in container 144 may thenbe mixed with an alcohol carrier and other excipients in container 166or 144 to form the psychoactive injectable composition. The injectablepsychoactive composition may then be stored in a vial 168, for example.

In other examples, parts of the apparatus may be reused or duplicated.For example, if desired, the elution fraction 156 may be reloaded intothe container 144 for pH adjustment and the steps from thereon can berepeated to allow for further purification of the obtained purifiedpsychoactive alkaloid solution.

I. Conclusion

Throughout the description, specific details have been set forth inorder to provide a more thorough understanding of the invention.However, the invention may be practiced without these particulars. Inother instances, well known elements have not been shown or described indetail and repetitions of steps and features have been omitted to avoidunnecessarily obscuring the invention. Accordingly, the specificationand drawings are to be regarded in an illustrative, rather than arestrictive, sense.

It will be clear to one having skill in the art that further variationsto the specific details disclosed herein can be made, resulting in otherembodiments that are within the scope of the invention disclosed. Stepsin the flowchart may be performed in a different order, other steps maybe added, or one or more may be removed without altering the mainoutcome of the processes. In some embodiments, the extract may bereplaced with a synthetic psychoactive alkaloid source or composition.The process may be scaled up using larger quantities and a modifiedapparatus.

All parameters, dimensions, materials, quantities and configurationsdescribed herein are examples only and may be changed depending on thespecific embodiment. Numbers are given to the nearest significantfigure, or to 10%, whichever is the greater. Temperatures that have beengiven to the nearest degree include all temperatures within a range of±0.5° C. of the given value. Integer values of pH are understood to bespecified to ±0.5 or, when expressed as a decimal, to the nearestsignificant digit, unless specifically indicated otherwise.

Any of the solvents described herein may be used with any of theorganisms that have psychoactive alkaloids.

As will be understood by one skilled in the art, for any and allpurposes, such as in terms of providing a written description, allranges disclosed herein also encompass any and all possible subrangesand combinations of subranges thereof. Any listed range can be easilyrecognized as sufficiently describing and enabling the same range beingbroken down into at least equal halves, thirds, quarters, fifths,tenths, etc. As a non-limiting example, each range discussed herein canbe readily broken down into a lower third, middle third and upper third,etc. For example, if a range is given as m-q, then the ranges m-n, n-pand p-q are included each as a separate embodiment, where n and p areany values that satisfy m<n<p<q.

In some embodiments, as the ranges become narrower and more centralcompared to the greatest range, the properties of the embodimentsgenerally become more balanced, such properties being solubility,viscosity, flowability, stability, potency, immediate potency, delayedpotency, cost of production, efficiency of production, production time,compatibility of the psychoactive alkaloid composition, psychoactiveefficacy of the psychoactive alkaloid extract, psychoactive efficacy ofthe psychoactive alkaloid composition and so on. As the ranges becomenarrower towards one extreme or other of the widest range, a particularproperty of the composition or process generally becomes more pronouncedrelative to the other properties. The specific range is to be chosendepending on how the properties are to be traded off against each other.As will also be understood by one skilled in the art, all language suchas “up to,” and the like include the number recited, and any toleranceexplicitly or implicitly associated with it, and refer to ranges whichcan be subsequently broken down into subranges as discussed above.Finally, as will be understood by one skilled in the art, a rangeincludes each individual member.

Accordingly, the scope of the invention is to be construed in accordancewith the substance defined by the claims.

The invention claimed is:
 1. A liquid, injectable psychoactive alkaloidcomposition comprising, by weight: 0.1-50% of a psychoactive alkaloidcomponent; 25-89.9% of a solvent carrier; 0-20% of a tonicity modifier;0-10% of a pH modifier; 0-5% of a bioavailability enhancer; and 0-5% ofan antioxidant, preservative or mixture thereof.
 2. The composition ofclaim 1, wherein the psychoactive alkaloid component comprises moredephosphorylated psychoactive alkaloid than phosphorylated psychoactivealkaloid.
 3. The composition of claim 2, wherein: the phosphorylatedpsychoactive alkaloid is psilocybin, baeocystin, norbaeocystin,aeruginascin, or any combination selected therefrom; and thedephosphorylated psychoactive alkaloid is psilocin, bufotenine,bufotenidine, norpsilocin, 4-hydroxytryptamine, 4-hydroxy-N, N,N-trimethyltryptamine, N, N, N-trimethyl-4-hydroxytryptamine, or anycombination selected therefrom.
 4. The composition of claim 1, whereinthe psychoactive alkaloid component comprises phosphorylatablepsychoactive alkaloid that is 100% dephosphorylated.
 5. The compositionof claim 1, comprising 10-20% of the psychoactive alkaloid component,wherein the psychoactive alkaloid component is an extract.
 6. Thecomposition of claim 1, wherein the psychoactive alkaloid component isan extract that has a total psychoactive alkaloid content ranging from0.1% to 99% by weight.
 7. The composition of claim 6, wherein theextract is a purified extract, and the purified extract has a totalpsychoactive alkaloid content ranging from 10% to 99% by weight.
 8. Thecomposition of claim 6, wherein the extract comprises naturallyoccurring substances from the group consisting of fats, sugars,carbohydrates, chitin, chitosan, minerals, waxes, proteins, or anycombination selected therefrom, and the naturally occurring substancesare present in the extract in a concentration ranging from 1% to 99.9%by weight.
 9. The composition of claim 1, wherein the psychoactivealkaloid component is synthetic.
 10. The composition of claim 1, whereinthe solvent carrier is water, ethanol, PEG, PEG 300, PEG 400, PEG 600,PEG 3350, PEG 4000, PG, glycerine, benzyl benzoate, castor oil,cottonseed oil, N,N dimethylacetamide, N-methyl-2-pyrrolidone, peanutoil, poppyseed oil, safflower oil, sesame oil, soybean oil, vegetableoil or any combination selected therefrom.
 11. The composition of claim1, wherein the antioxidant, preservative or mixture thereof is presentin the composition and is benzyl alcohol, ascorbic acid, methylparaben,propylparaben, benzalkonium chloride, thiomersal, sodium bisulfite,sodium meta bisulfite, thiourea or any combination selected therefrom.12. The composition of claim 1, wherein the tonicity modifier is presentin the composition and is sodium carboxymethyl cellulose, acacia,gelatin, methyl cellulose, polyvinyl pyrrolidone or any combinationselected therefrom.
 13. The composition of claim 1, comprising 0.5-2% ofthe bioavailability enhancer.
 14. The composition of claim 1, comprisinga pH modifier, wherein the pH modifier is present in the composition andis acetate, ammonium sulfate, ammonium hydroxide, arginine, asparticacid, benzene sulfonic acid, sodium benzoate, benzoic acid, sodiumbicarbonate, boric acid, sodium borate, sodium carbonate, carbondioxide, citric acid, sodium citrate, trisodium citrate, disodiumcitrate, diethyanolamine, glucono delta lactone, glycine, histidine,hydrochloric acid, hydrobromic acid, lysine, maleic acid, maglumine,methanesulfonic acid, monoethanolamine, phosphoric acid, monobasicpotassium phosphate, dibasic, potassium phosphate, tribasic sodiumphosphate, dibasic sodium phosphate, monobasic sodium phosphate, sodiumhydroxide, sodium succinate, disodium succinate, sulfuric acid, tartaricacid, sodium tartrate, tromethamine (TRIS) or any combination selectedtherefrom.
 15. The composition of claim 14, comprising up to 5% byweight of the pH modifier.
 16. The composition of claim 1 having a pH ina range of 4.5 to 5.5.
 17. The composition of claim 1 having a pH of5±0.25.
 18. The composition of claim 1, wherein a total psychoactivealkaloid content in the composition is defined as a percentage to twodecimal places.
 19. The composition of claim 1, wherein the psychoactivealkaloid component has a pH of 8.47±0.25.
 20. The composition of claim1, comprising 60-80% by weight of the solvent carrier.
 21. Thecomposition of claim 1, comprising 2.5-5% of the antioxidant,preservative or mixture thereof.
 22. A process for obtaining a liquid,injectable psychoactive alkaloid composition, the process comprising:extracting psychoactive alkaloid from a dried powdered psychoactivealkaloid source using an acidified solvent with a pH of 3.5 or lower, toobtain a psychoactive alkaloid liquid; adjusting the pH of thepsychoactive alkaloid liquid to a pH ranging from 4.5-5.5; evaporatingthe acidified solvent from the psychoactive alkaloid liquid to obtain apsychoactive alkaloid extract; and mixing, by weight: 0.1-50% of thepsychoactive alkaloid extract; 25-89.9% of a solvent carrier; 0-20% of atonicity modifier; 0-10% of a pH modifier; 0-5% of a bioavailabilityenhancer; and 0-5% of an antioxidant, preservative or mixture thereof;to form the liquid, injectable psychoactive alkaloid composition. 23.The process of claim 22, wherein the acidified solvent has a pH rangingfrom 0.5-3.5.
 24. The process of claim 22, wherein the extracting stepcomprises: mixing the dried powdered psychoactive alkaloid source withthe acidified solvent to obtain a slurry; and filtering the slurry toobtain a filtrate residue and the psychoactive alkaloid liquid.
 25. Theprocess of claim 22, wherein the psychoactive alkaloid componentcomprises phosphorylatable psychoactive alkaloid that is 100%dephosphorylated.
 26. The process of claim 22, comprising purifying thepsychoactive alkaloid extract prior to the mixing step by: contactingthe psychoactive alkaloid extract, in solution, with a resinous materialto obtain an adsorbed psychoactive alkaloid; eluting the adsorbedpsychoactive alkaloid using a solvent to obtain a purified psychoactivealkaloid solution, wherein the solvent is water, an organic solvent or acombination thereof, under basic, acidic or neutral pH; and evaporatingthe solvent to obtain a purified form of the psychoactive alkaloidextract.
 27. The process of claim 22, comprising: interrupting theevaporation step to result in a concentrated slurry; measuring apsychoactive alkaloid content in the concentrated slurry; measuring adry mass content in the concentrated slurry; using the psychoactivealkaloid content, the dry mass content and a specified concentration forthe psychoactive alkaloid in the psychoactive alkaloid extract todetermine a quantity of excipient to add to the concentrated slurry inorder to obtain the specified concentration of the psychoactive alkaloidin the psychoactive alkaloid extract; adding the excipient to thepsychoactive alkaloid extract to standardize the psychoactive alkaloidextract; and continuing the evaporation step.
 28. The process of claim22, comprising including at least some of the bioavailability agent inthe liquid, psychoactive alkaloid composition.
 29. The process of claim22, comprising including at least some of the pH modifier in the liquid,psychoactive alkaloid composition to result in the psychoactive alkaloidcomposition having a pH between 4.5 and 5.5.